NCT01850953View on ClinicalTrials.gov

Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia

PHASE4CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

CravingSmokingSchizophrenia

Interventions

DRUG

Varenicline

This is an approved smoking cessation medication.

DRUG

Placebo

Trial Locations (1)

M5S 2S1

Centre for Addiction and Mental Health, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Centre for Addiction and Mental Health

OTHER